UBS AG upgraded shares of Hospira (NYSE: HSP) from a sell rating to a neutral rating in a research report sent to investors on Friday morning. The firm currently has $30.00 price target on the stock, up from their previous price target of $28.00.
Shares of Hospira traded up 1.34% during mid-day trading on Friday, hitting $31.00. Hospira has a one year low of $28.62 and a one year high of $38.49. The stock’s 50-day moving average is currently $32.09. The company has a market cap of $5.128 billion and a P/E ratio of 114.14.
A number of other firms have also recently commented on HSP. Analysts at RBC Capital cut their price target on shares of Hospira from $26.00 to $25.00 in a research note to investors on Wednesday, March 6th. Separately, analysts at Gabelli downgraded shares of Hospira from a buy rating to a hold rating in a research note to investors on Tuesday, February 26th. Finally, analysts at Barclays Capital cut their price target on shares of Hospira from $34.00 to $32.00 in a research note to investors on Thursday, February 14th. They now have an equal weight rating on the stock.
One research analyst has rated the stock with a buy rating, twelve have assigned a hold rating, and three have given a sell rating to the company’s stock. The stock currently has a consensus rating of hold and a consensus target price of $29.67.
Hospira, Inc. (Hospira) is a specialty pharmaceutical and medication delivery company. Hospira’s portfolio includes generic acute-care and oncology injectables, as well as integrated infusion therapy and medication management systems.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.
